In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

The mortality rate associated with Vibrio vulnificus sepsis remains high. An in vitro time-kill assay revealed synergism between tigecycline and ciprofloxacin. The survival rate was significantly higher in mice treated with tigecycline plus ciprofloxacin than in mice treated with cefotaxime plus minocycline. Thus, combination treatment with tigecycline-ciprofloxacin may be an effective novel antibiotic regimen for V. vulnificus sepsis.

Kim SE ，Kim HK ，Choi SM ，Yu Y ，Kim UJ ，Darboe KS ，Kang SJ ，Park KH ，Kang G ，Kim YR ，Rhee JH ，Jung SI ，Jang HC ... -  《-》

In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.

Jang HC ，Choi SM ，Kim HK ，Kim SE ，Kang SJ ，Park KH ，Ryu PY ，Lee TH ，Kim YR ，Rhee JH ，Jung SI ，Choy HE ... -  《PLoS One》

In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.

The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the time-kill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 μg/mL, 0.03-0.06 μg/mL, and 0.03-0.06 μg/mL, respectively. In time-killing studies, at the concentration of 1 × MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 × MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 × MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 × 105 CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 × 106 CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections.

Tang HJ ，Chen CC ，Lai CC ，Zhang CC ，Weng TC ，Chiu YH ，Toh HS ，Chiang SR ，Yu WL ，Ko WC ，Chuang YC ... -  《-》

In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.

Kim DM ，Lym Y ，Jang SJ ，Han H ，Kim YG ，Chung CH ，Hong SP ... -  《-》

Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection.

Chiang SR ，Tang HJ ，Chang PC ，Cheng KC ，Ko WC ，Chen CH ，Chuang YC ... -  《-》